$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What are the effects and functions of Revumenib-Revuforj
2026-02-01 22:25:32
Check Details
Effect evaluation and daily medication precautions after taking Platinib (Pujihua)
2026-02-01 22:25:32
Check Details
Analysis on the feasibility of purchasing Laibo Leisheng (Davico) in China and overseas purchasing channels
2026-02-01 22:25:32
Check Details
What are the side effects of capmatinib (Touradda) and how to reduce adverse drug reactions
2026-02-01 22:25:32
Check Details
Analysis of the efficacy of the Lao version of sotorasibu (AMG 510) and its differences with the original drug
2026-02-01 22:25:32
Check Details
Introduction to the price of generic drugs of Adagrasib (Krazati) and the purchasing channels of various versions of the drug
2026-02-01 22:25:32
Check Details
Whether larotrectinib (Vitaika) is suitable for patients with glioma and its clinical effect evaluation
2026-02-01 22:25:32
Check Details
How long does it usually take to take Selinexol (Silvio) to achieve obvious therapeutic effects?
2026-02-01 22:25:32
Check Details
Whether Vigabatrin (Ocoda) is a prohibited drug and related regulations
2026-02-01 22:25:32
Check Details
Clinical analysis of the mechanism of action and therapeutic effect of mobosetinib (Anweili)
2026-02-01 22:25:32
Check Details
Analysis of potential risks of Tepotinib (Tuodekang) in the treatment of metastatic non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Analysis of the mechanism of action and targeted signaling pathways of regorafenib (Belvango)
2026-02-01 22:25:32
Check Details
1
2
...
1968
1969
1970
1971
1972
1973
1974
...
10227
10228
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
2
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
7
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
8
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
9
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
10
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
11
Anagrelide vs. Hydroxyurea in Essential Thrombocythemia: Efficacy Profiles and Clinical Positioning
12
SCEMBLIX (Asciminib) Side Effect Management & Special Population Guide